| Acenocoumarol versus Nadroparin | |||
| Hamulyak, 1994 | Acenocoumarol versus Nadroparin 60 anti-Xa IU /kg x1 | THR or TKR (stratified) | single blind Follow-up duration: Day 10 ± 2 |
| Acenocoumarol versus Reviparin | |||
| Samama, 2001 | Acenocoumarol versus Reviparin 4200 anti-Xa IU x1 | THR | Open Follow-up duration: 6 weeks |
| Acenocoumarol versus unfractionated heparin | |||
| van Geloven, 1977 | Acenocoumarol versus UFH 4000 ·x2 | THR | double blind Follow-up duration: NA |
| apixaban versus enoxaparin | |||
| ADVANCE 3, 2010 NCT00423319 | apixaban 2.5mg twice daily for 35 days versus enoxaparin 40mg once daily for 35 days | patients undergoing elective total hip replacement surgery | double blind Follow-up duration: 35 days (+60) 21 countries |
| apixaban versus enoxaparin (europe regimen) | |||
| ADVANCE 2, 2010 NCT00452530 | apixaban 2.5mg twice daily during 12 days versus enoxaparin 40mg once daily 12 days | patients undergoing elective unilateral or bilateral total knee replacement | double blind Follow-up duration: 12 days 27 countries |
| apixaban versus enoxaparin (US regimen) | |||
| APROPOS 2.5mg, 2007 NCT00097357 | apixaban 2.5mg BID for 12 days versus enoxaparin 30mg twice daily for 12 days | patients undergoing elective total knee replacement surgery | double blind Follow-up duration: 12 days |
| ardeparin versus placebo | |||
| Levine, 1996 | ardeparin 50/kgx2 +elastic stockings versus Placebo+elastic stockings | Knee | double blind Follow-up duration: 14 days |
| Aspirin versus no treatment | |||
| Pasteyer, 1977 | Aspirin 1000mg daily + Hep versus control (Hep alone) | Elective orthopaedic surgery | Follow-up duration: 2 weeks |
| Rocha, 1986 | Aspirin 250mg or 1000mg daily versus control (combination of heparin plus dihydroergotamine) | total hip replacement | open Follow-up duration: 1 weeks |
| Aspirin versus placebo | |||
| Zekert-I , 1974 | Aspirin 1500mg daily versus placebo | patients undergoing surgery of hip-joint proximal fractures | double-blind |
| Powers , 1976 | A1300 versus placebo | traumatic orthopaedic surgery | |
| Erfurt-B , 1979 | A1500 versus placebo | traumatic orthopaedic surgery | double-blind |
| aspirin versus placebo | |||
| PEP hip-fracture, 2000 | aspirin 160mg/d started preoperatively and continued for 35 days versus placebo | patients undergoing surgery for hip fracture | Double blind Follow-up duration: 35 days Australia, New Zealand, South Africa, |
| Aspirin versus placebo | |||
| Stockholm-I, 1975 | Aspirin 2000mg daily versus placebo | elective surgery of the hip | double blind Follow-up duration: 2 weeks |
| Harris-I, 1977 | Aspirin 1200mg daily versus placebo | patients over 40 years of age, who had undergone total hip replacement | double-blind Follow-up duration: 1 weeks |
| McKenna-I, 1980 | Aspirin 975mg or 3900mg daily versus placebo | total knee replacement | double-blind Follow-up duration: 2 weeks |
| Sautter, 1983 | Aspirin 900mg daily + sulfinpyrazone versus placebo | patient with total hip replacement | Follow-up duration: 3 weeks |
| McBride, 1983 | A1800+Dipyridamole versus placebo | Elective orthopaedic surgery | Follow-up duration: 1 weeks |
| aspirin + dipyridamol versus no treatment | |||
| Morris-B , 1977 | Aspirin 900 mg daily + dipyridamole versus control | elderly patients with hip fractures | open |
| Lyon-I, 1975 | Aspirin 1500 mg daily + Dipyridamole versus control | Elective orthopaedic surgery | Follow-up duration: 2 weeks |
| aspirin + dipyridamol versus placebo | |||
| Encke-II , 1976 | Aspirin 1500mg daily, Aspirin 990mg daily + dipyridamol versus placebo | patients with abdominal operations | double-blind |
| Hamburg, 1976 | A+Dipyridamole,A1000 versus placebo | Elective orthopaedic surgery | Follow-up duration: 3 weeks |
| certoparine + DHE versus Unfractionated heparin | |||
| Haas , 1987 | Sandoz +0.5mg DHE versus Unfractionated heparin | Elective hip | |
| Lassen, 1989 | certoparin 3000+0.5mg DHE x1 versus placebo | Hip fracture | double blind Follow-up duration: 6 days |
| Lassen, 1988 | certoparin 3000+0.5mg DHE, x1 versus Placebo | Elective hip | double blind Follow-up duration: 6 days |
| compression stocking group versus control (on top fondaparinux) | |||
| Cohen (L8405), 2007 | fondaparinux 2.5mg plus graduated compression stockings versus fondaparinux 2.5mg daily | patients undergoing elective or emergency hip surgery | open Follow-up duration: 42 days Brazil, UK, Hong Kong, Spain |
| dabigatran 150mg versus enoxaparin | |||
| RE-NOVATE (150mg), 2007 NCT00168818 | dabigatran etexilate 150 mg q.d. 28-35 days
versus Enoxaparin 40 mg q.d. for 28-25 days | Total hip replacement | double blind Follow-up duration: 28-35 days, median 33d Europe, Australia, South Africa |
| dabigatran 150mg versus enoxaparin (europe regimen) | |||
| RE-MODEL (150mg), 2007 | dabigatran etexilate 150 mg q.d. for 6-10 days versus Enoxaparin 40 mg q.d. for 6-10 days | Total knee replacement | double blind Follow-up duration: 6-10 days, mean 8 days Europe, Australia, South Africa |
| dabigatran 150mg versus enoxaparin (US regimen) | |||
| RE-MOBILIZE (150mg), 2008 | dabigatran etexilate 150 mg q.d. for 12-15 days
versus enoxaparin 30 mg SC BID after surgery for 12-15 days | Total knee replacement | double blind Follow-up duration: 12-15 days, median 14d US, Canada, Mexico, UK |
| dabigatran 220mg versus enoxaparin | |||
| RE-NOVATE 2, 0 NCT00657150 | dabigatran 220mg once daily for 28-35 Days versus enoxaparin 40mg subcutaneous once daily for 28-35 Days | patients undergoing total hip-replacement surgery | double-blind Follow-up duration: 28-35 days (mean 32d) |
| RE-NOVATE (220mg), 2007 NCT00168818 | dabigatran etexilate 220 mg q.d. for 28-35 days versus Enoxaparin 40 mg q.d. for 23-35 days | Total hip replacement | double blind Follow-up duration: 28-35 days, median 33d Europe, Australia, South Africa |
| dabigatran 220mg versus enoxaparin (europe regimen) | |||
| RE-MODEL (220mg), 2007 | dabigatran etexilate 220 mg q.d. 6-10 days
versus Enoxaparin 40 mg q.d. for 6-10 days | patients undergoing total knee replacement | double blind Follow-up duration: 6-10 days, mean 8 days Europe, Australia, South Africa |
| dabigatran 220mg versus enoxaparin (US regimen) | |||
| RE-MOBILIZE (220mg), 2008 | dabigatran etexilate 220 mg for 12-15 days
versus Enoxaparin 30mg SC BID after surgery for 12-15 days | Total knee replacement | double blind Follow-up duration: 12-15 days, median 14d US, Canada, Mexico, UK |
| dalteparin versus Dextran | |||
| Matzsch , 1991 | dalteparin versus Dextran | Elective hip | |
| Eriksson , 1988 | dalteparin versus Dextran | Elective hip | |
| Matzsch , 1988 | dalteparin versus Dextran | Elective hip | |
| dalteparin versus placebo | |||
| Jorgensen, 1989 | dalteparin 5000 x1 versus Placebo | Hip fracture | double blind Follow-up duration: 9 days |
| Torholm, 1991 | dalteparin 5000x1 versus Placebo | Elective hip | double blind Follow-up duration: 9 days |
| dalteparin versus Unfractionated heparin | |||
| Binsack , 1986 | dalteparin versus Unfractionated heparin | Elective hip | |
| Barre , 1987 | dalteparin versus Unfractionated heparin | Elective hip | |
| Dechavanne , 1989 | dalteparin versus Unfractionated heparin | Elective hip | |
| Eriksson , 1989 | dalteparin versus Unfractionated heparin | Elective hip | |
| Haas , 1985 | dalteparin versus Unfractionated heparin | Elective hip | |
| Monreal , 1989 | dalteparin versus Unfractionated heparin | Hip | |
| desirudin versus enoxaparin | |||
| Ericksson, 1997 | desirudin 15mg SC twice daily for 8-12 days versus enoxaparin 40mg once daily for 8-12 days | Patients who undergo total hip replacement | double blind Europe |
| desirudin versus UFH | |||
| REVASC, 1997 | desirudin 15mg twice daily versus unfractionated heparin 5000 IU three times a day | patients having a primary elective total hip replacement | |
| Eriksson, 1996 | recombinant hirudin, desirudin (CGP 39393) 10, 15, or 20 mg twice daily started just before surgery and continued for 8-11 days versus unfractionated heparin 5000 IU three times daily started just before surgery and continued for 8-11 days | patients undergoing elective hip surgery | double blind Europe |
| dipyridamol versus no treatment | |||
| Morris-A , 1977 | dipyridamole versus control | elderly patients with hip fractures | open |
| edoxaban versus enoxaparin (short duration) | |||
| STARS J-V, 0 NCT01181167 | edoxaban 30 mg once daily for 11 to 14 days versus subcutaneous enoxaparin 2,000 IU, equivalent to 20 mg, twice daily (BID) for 11 to 14 days | total hip arthroplasty | double-blind japan |
| enoxaparin versus Dextran | |||
| DES Group , 1991 | Enoxaparin versus Dextran | Elective hip | |
| enoxaparin versus no treatment | |||
| Warwick, 1995 | enoxaparin 4000x1 + elastic stockings versus no treatment + elastic stockings | Elective hip | open Follow-up duration: 8-10 days |
| enoxaparin versus placebo | |||
| Kalodiki, 1996 | enoxaparin 4000x1 versus Placebo | Elective hip | double blind Follow-up duration: discharge (8-12 days ) |
| Leclerc, 1991 | Enoxaparin 3000 x2 versus Placebo | Knee | double blind Follow-up duration: 14 days |
| Samama, 1997 | enoxaparin 4000x1+elastic stockings versus Placebo+elastic stockings | Elective hip | double blind Follow-up duration: 8-12 days |
| Turpie, 1986 | Enoxaparin 3000 x2 versus Placebo | Elective hip | double blind Follow-up duration: 14 days or discharge |
| enoxaparin versus Unfractionated heparin | |||
| Levine , 1991 | Enoxaparin versus Unfractionated heparin | Elective hip | |
| Planes , 1988 | Enoxaparin versus Unfractionated heparin | Elective hip | |
| extended prophylaxis versus standard prophylaxis | |||
| PENTHIFRA–PLUS (Eriksson), 2003 | 25-31 days of fondaparinux 2.5-mg once-daily versus 6-8 days of fondaparinux 2.5-mg once-daily | patients undergoing hip fracture surgery | double blind Follow-up duration: 19-23 days |
| Flurbiprofen versus no treatment | |||
| Mocris-C , 1977 | Flurbiprofen versus control | elderly patients with hip fractures | open |
| fluxum versus Unfractionated heparin | |||
| Chiapuzzo , 1988 | Fluxum versus Unfractionated heparin | Elective hip | |
| Pini , 1989 | Fluxum versus Unfractionated heparin | Hip | |
| fondaparinux versus enoxaparin | |||
| L8541, 0 | fondaparinux 2.5mg subcutaneous once-daily for 7+/-2 days versus enoxaparin 40mg s.c. once-daily | chinese patients undergoing major orthopaedic surgery of the lower limbs | single-blind Follow-up duration: 9 days (49d) China |
| L8635, 0 | Fondaparinux 2.5mg once daily subcutaneously for 7 days versus enoxaparin 40mg once daily SC for 7 days | Taiwanese patients undergoing elective knee replacement | open, blind assessment Follow-up duration: 10 days Taiwan |
| PENTAMAKS (Bauer), 2001 | fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery versus enoxaparin 30mg twice daily (North america recommendation) | elective major knee surgery | double blind Follow-up duration: 11 days North america |
| PENTHIFRA (Eriksson), 2001 | fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery versus enoxaprin 40mg once daily | hip fracture surgery | double blind Follow-up duration: 11 days 21 countries |
| EPHESUS (Lassen), 2002 | fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery versus enoxaprin 40mg once daily | elective hip replacement surgery | double blind Follow-up duration: 11 days (6 weeks) 16 European countries |
| PENTATHLON (Turpie), 2002 | fondaparinux 2.5-mg once-daily subcutaneous, starting 6 hours after surgery versus enoxaparin 30mg twice daily (North america recommendation) | elective hip replacement surgery | double blind Follow-up duration: 11 days USA, Canada, Australia |
| Turpie, 2001 | pentasaccharide Org31540/SR90107A subcutaneous once daily at doses 0.75 mg, 1.5 mg, 3.0 mg, 6.0 mg, and 8.0 mg versus enoxaparin 30mg once daily subcutaneous | patients undergoing total hip replacement | double blind Follow-up duration: >15 days US, Canada, Autralia |
| fondaparinux versus placebo | |||
| DRI4757, 0 | fondaparinux subcutaneously at 0.75, 1.5, 2.5, and 3.0 mg for at least 10 calendar days, (with a maximum of 14 days) versus placebo | Japanese patients undergoing elective total knee replacement surgery | double blind Follow-up duration: 14 days Japan |
| Hydroxychloroquine versus no treatment | |||
| Massachusetts-I , 1981 | Aspirin 1200mg daily, Aspirin 1200mg daily + hydroxychloroquine 300 mg b.i.d. versus control | patients with upper femoral fractures | open |
| Hydroxychloroquine versus placebo | |||
| Danish-A , 1976 | Hydroxychloroquine sulphate versus placebo | patients with fractures of the hip, pelvis, or thoracolumbar spine | double-blind |
| Danish-B , 1976 | Hydroxychloroquine sulphate versus placebo | patients with fractures of the hip, pelvis, or thoracolumbar spine | |
| Massachusetts-II, 1976 | Hydroxychloroquine 600mg daily versus placebo | fractures or orthopaedic operations involving the skeleton between the knee and the pelvis | Follow-up duration: 3 weeks |
| Cooke, 1977 | Hydroxychloroquine versus placebo | elective surgery on the hip | double-blind Follow-up duration: 2 weeks |
| Hume-A, 1977 | Hydroxychloroquine versus placebo | total hip replacement | Follow-up duration: 2 weeks |
| Stockholm-II, 1981 | Hydroxychloroquine versus placebo | total hip replacement | Follow-up duration: 2 weeks |
| nadroparin versus no treatment | |||
| Yoo, 1997 | nadroparin 41/kgx1 days 1-3, 62/kg x1 days 4-11+elastic stockings versus no treatment | Elective hip | open Follow-up duration: 10 days |
| nadroparin versus placebo | |||
| Sourmelis, 1995 | nadroparin 3075x1 preop, 6150x1 post op versus Placebo | Hip fracture | double blind Follow-up duration: 10-12 days |
| nadroparin versus Unfractionated heparin | |||
| Leyvraz, 1991 | Fraxiparin versus Unfractionated heparin | Elective hip | |
| out of hospital Ardeparin versus standard prophylaxis | |||
| Heit, 2000 | in hospital thromboprophylaxis followed by out of hospital Ardeparin 100 IU/kg once a day for a total duration of 42 days versus Ardeparin 50 IU/kg twice a day for 4-10 days | THR or TKR | |
| out of hospital Dalteparin versus standard prophylaxis | |||
| Dahl, 1997 | in hospital thromboprophylaxis followed by out of hospital Dalteparin 5000 IU once a day for a total duration of 35 days versus Dalteparin 5000 IU once a day for 7 days (dextran day 0 and day 1) | THR | |
| Lassen, 1998 | in hospital thromboprophylaxis followed by out of hospital Dalteparin 5000 IU once a day for a total duration of 35 days versus Dalteparin 5000 IU once a day for 7 days | THR | |
| Hull, 2000 | in hospital thromboprophylaxis followed by out of hospital Dalteparin 5000 IU once a day for a total duration of 35 days versus Dalteparin 5000 IU once a day or warfarin for 6 days | THR | |
| out of hospital Enoxaparin versus standard prophylaxis | |||
| Bergqvist, 1996 | in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 30 days versus Enoxaparin 40 mg once a day for 10-11 days | THR | |
| Planes, 1996 | in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 35 days versus Enoxaparin 40 mg once a day for 13-15 days | THR | |
| Comp, 2001 | in hospital thromboprophylaxis followed by out of hospital Enoxaparin 40 mg once a day for a total duration of 27-29 days versus Enoxaparin 30 mg twice a day for 7-10 days | THR or TKR | |
| out of hospital Nadroparin versus standard prophylaxis | |||
| NPHDO, 1998 | in hospital thromboprophylaxis followed by out of hospital Nadroparin weight-adjusted for a total duration of 37-38 days versus Nadroparin weight-adjusted for 16-17 days | THR | |
| out of hospital UFH versus standard prophylaxis | |||
| Manganelli, 1998 | in hospital thromboprophylaxis followed by out of hospital UFH 5000 IU three times a day for a total duration of 30 days versus UFH 5000 IU three times a day for 15 days | THR | |
| Phenindione versus no treatment | |||
| Eskeland, 1966 | Phenindione versus No treatment | HFS | Open Follow-up duration: 3 months |
| Hamilton, 1970 | Phenindione versus No treatment | HFS | Open Follow-up duration: 3–10 months |
| RA233 versus placebo | |||
| Wood , 1973 | RA233; Aspirin 600mg daily +RA233 versus placebo | traumatic orthopaedic surgery | |
| rivaroxaban versus enoxaparin | |||
| RECORD 1, 2008 NCT00329628 | rivaroxaban 10mg once daily for 35 days versus enoxaparin 40mg subcutaneous once daily for 31-39 days | patients undergoing total hip arthroplasty | double blind Follow-up duration: 36 days (range 30-42) 27 countries worldwide |
| rivaroxaban versus enoxaparin (europe regimen) | |||
| RECORD 3, 2008 NCT00361894 | rivaroxaban 10 mg once daily for 10- 14 days versus enoxaparin 40 mg subcutaneous once daily for 10-14 days | patients undergoing total knee arthroplasty | double blind Follow-up duration: 13-17 days 19 countries worldwide |
| rivaroxaban versus enoxaparin (short duration) | |||
| ODIXa-HIP 10mg, 2006 | rivaroxaban 10mg daily for 5–9 days versus once-daily subcutaneous enoxaparin dose of 40 mg for 5–9 days | patients undergoing elective total hip replacement | double blind Follow-up duration: 5-9 days Europe, Israel |
| rivaroxaban versus enoxaparin (US regimen) | |||
| ODIXa-KNEE, 2005 | BAY 59-7939 5mg b.i.d. for 5–9 days versus enoxaparin 30 mg b.i.d. for 5–9 days | patients undergoing elective total knee replacement | double blind Follow-up duration: 5-9 days North America |
| RECORD 4, 2009 NCT00362232 | rivaroxaban 10mg once daily for 10 to 14 days versus enoxaparin 30 mg twice daily by subcutaneous injection for 10-14 days | patients who had undergone total-knee-replacement surgery | double blind Follow-up duration: 40 days 12 countries |
| rivaroxaban (long duration) versus enoxaparin (short duration) | |||
| RECORD 2, 2008 NCT00332020 | extended thromboprophylaxis with rivaroxaban 10mg once daily for 31-39 days versus enoxaparin 40mg subcutaneous once daily for 10-14 days | patients undergoing elective total hip replacement | double blind Follow-up duration: 30-42 days 21 countries worldwide |
| semuloparin versus enoxaparin | |||
| SAVE-HIP1, 2012 NCT00697099 | Semuloparin 20 mg once-daily versus Enoxaparin 40 mg once-daily | ||
| SAVE-KNEE, 2012 NCT00718224 | Semuloparin 20 mg once-daily versus Enoxaparin 30 mg twice-daily | ||
| SAVE-HIP 2, 2012 NCT00721760 | Semuloparin 20 mg once-daily versus Enoxaparin 40 mg once-daily | hip fracture surgery | |
| SR123781A versus enoxaparin | |||
| DRIVE, 2008 NCT00338897 | SR123781A for 5-10 days, doses ranging from 0.25 to 4.0 mg daily for 10 days versus enoxaparin 40 mg | patients undergoing total hip replacement surgery | double blind Follow-up duration: 5-10 days 12 countries |
| Ticlopidine versus placebo | |||
| McKenna-II, 1983 | Ticlopidine versus placebo | Elective orthopaedic surgery | Follow-up duration: 2 weeks |
| Lyon-II, 3000 | Ticlopidine versus placebo | Elective orthopaedic surgery | Follow-up duration: 3 weeks |
| Gardecki, 3000 | Ticlopidine versus placebo | Elective orthopaedic surgery | Follow-up duration: 2 weeks |
| tinzaparin versus placebo | |||
| Lassen, 1991 | tinzaparin 50/kg x1 +elastic stockings versus Placebo+elastic stockings | Elective hip | double blind Follow-up duration: 8-10 days |
| UFH versus no treatment | |||
| Bergqvist , 1979 | UFH twice daily for 5 days versus no treatment | elective orthopedic surgery | |
| Bergqvist, 1979 | UFH twice daily for 5 days versus no treatment | traumatic orthopedic surgery | |
| Dechavanne, 1974 | UFH 3 times daily for 10 days versus no treatment | elective orthopedic surgery | |
| Dechavanne, 1975 | UFH 3 times daily for 10 days versus no treatment | elective orthopedic surgery | |
| Galasko , 1976 | UFH twice daily (duration unknown) versus no treatment | traumatic orthopedic surgery | |
| Gallus , 1973 | UFH 3 times daily for A versus no treatment | traumatic orthopedic surgery | |
| Mannucci , 1976 | UFH 3 times daily for 7 days versus no treatment | elective orthopedic surgery | |
| Morris, 1974 | UFH twice daily for 10 days versus no treatment | elective orthopedic surgery | |
| Morris , 1977 | UFH 3 times daily for 10 days versus no treatment | traumatic orthopedic surgery | |
| VTCSG, 1975 | UFH twice daily for 10 days versus no treatment | elective orthopedic surgery | |
| Welin-Berger, 1982 | UFH twice daily for 7 days versus no treatment | elective orthopedic surgery | |
| UFH versus placebo | |||
| Abraham-Inpijn , 1975 | UFH twice daily for 8 days versus placebo | elective orthopedic surgery | |
| Hampson, 1974 | UFH 3 times daily for 7- 10 days versus placebo | elective orthopedic surgery | |
| Lahnborg, 1980 | UFH twice daily for 10 days versus placebo | traumatic orthopedic surgery | |
| Lowe , 1981 | UFH twice daily for 16 days versus placebo | elective orthopedic surgery | |
| Moskovitz, 1978 | UFH 3 times daily for 7 days versus placebo | traumatic orthopedic surgery | |
| Moskovitz, 1978 | UFH 3 times daily for 7 days versus placebo | elective orthopedic surgery | |
| Svend-Hansen, 1981 | UFH 3 times daily for 14 days versus placebo | traumatic orthopedic surgery | |
| Williams , 1978 | UFH twice daily for 14 days versus placebo | elective orthopedic surgery | |
| Xabregas , 1977 | UFH twice daily for 14 days versus placebo | traumatic orthopedic surgery | |
| Warfarin versus Ardeparin | |||
| RD Heparin, 1994 | Warfarin versus Ardeparin 50 anti-Xa IU /kg or 90 anti-Xa IU /kg x1 | THR or TKR | Open Follow-up duration: 3 months |
| Heit, 1997 | Warfarin versus Ardeparin 25, 35, 50 anti-Xa U /kg x2 | TKR | double blind Follow-up duration: Days 5–14 |
| Warfarin versus Aspirin | |||
| Lotke, 1997 | Warfarin versus Aspirin 325 mg x2 | THR or TKR (stratified) | Open Follow-up duration: 6 months |
| Powers, 1989 | Warfarin versus Aspirin 650 mg x2 | HFS | Open Follow-up duration: 3 months |
| Warfarin versus Dalteparin | |||
| Francis, 1997 | Warfarin versus Dalteparin 5000 anti-Xa IU x1 | THR | Open Follow-up duration: Day 7 ± 2 |
| Hull, 2000 | Warfarin versus Dalteparin 5000 anti-Xa IU x1 | THR | double blind Follow-up duration: Day 6 ± 2 |
| Warfarin versus Danaparoid | |||
| Gerhart, 1991 | Warfarin versus Danaparoid 750 U x2 | HFS | Open Follow-up duration: 9 days |
| van Comp, 1998 | Warfarin versus Danaparoid 750 U x2 | THR | Open Follow-up duration: 3 months |
| Warfarin versus Dextran | |||
| Harris, 1972 | Warfarin versus Dextran 40 | THR | Open Follow-up duration: NA |
| Barber, 1977 | Warfarin versus Dextran 70 | THR | Open Follow-up duration: 11–14 days |
| Francis, 1983 | Warfarin versus Dextran 40 | THR or TKR (stratified) | Open Follow-up duration: 5–7 days |
| Myrhe, 1969 | Warfarin versus Dextran 70 | HFS | double blind Follow-up duration: 3 weeks |
| Warfarin versus Enoxaparin | |||
| Leclerc, 1996 | Warfarin versus Enoxaparin 30 mg x2 | TKR | double blind Follow-up duration: 6 months |
| Colwell, 1999 | Warfarin versus Enoxaparin 30 mg x2 | THR | Open Follow-up duration: 3 months |
| Fitzgerald, 2001 | Warfarin versus Enoxaparin 30 mg x2 | TKR | Open Follow-up duration: 3 weeks |
| Warfarin versus Intermittent pneumatic compression | |||
| Francis, 1992 | Warfarin versus IPC | THR | Open Follow-up duration: 6–8 days |
| Paiement, 1987 | Warfarin versus IPC | THR | Open Follow-up duration: 12 days |
| Bailey, 1991 | Warfarin versus IPC | THR | Open Follow-up duration: 5–7 days |
| Kaempffe, 1991 | Warfarin versus IPC | THR or TKR (stratified) | Open Follow-up duration: At least 2 months |
| Warfarin versus Logiparin | |||
| Hull, 1993 | Warfarin versus Logiparin 75 anti-Xa IU /kg x1 | THR or TKR (stratified) | double blind Follow-up duration: Day 14 or discharge |
| Warfarin versus no treatment | |||
| Pinto, 1970 | Warfarin versus No treatment | Hip surgery | Open Follow-up duration: > 3 weeks |
| Hume, 1973 | Warfarin versus No treatment | THR | Open Follow-up duration: Discharge |
| Morris, 1976 | Warfarin versus No treatment | HFS | Open Follow-up duration: 3 months |
| Powers, 1989 | Warfarin versus No treatment | HFS | Open Follow-up duration: 3 months |
| Warfarin versus placebo | |||
| Myrhe, 1969 | Wwarfarin versus Placebo | HFS | double blind Follow-up duration: 3 weeks |
| Warfarin versus Sudoxicam | |||
| Hume, 1973 | Warfarin versus Sudoxicam | THR | single blind Follow-up duration: Discharge |
| Warfarin versus unfractionated heparin | |||
| Hume, 1973 | Warfarin versus UFH 5000 x3 | THR | Open Follow-up duration: Discharge |
| Barber, 1977 | Warfarin versus UFH 5000 x2 | THR | Open Follow-up duration: 11–14 days |
| ximelagatran versus Dalteparin | |||
| METHRO I, 2002 | Melagatran 1–4 mg s.c. immediately before surgery, melagatran at 20.00 hours, then ximelagatran 6–24 mg orally b.d. for 6–9 days versus Dalteparin 5000 IU o.d., started evening before surgery for 6–9 days | adults undergoing hip or knee replacement | open Follow-up duration: 6–9 days Swedish |
| METHRO II, 2002 | Melagatran 1–3 mg s.c. immediately before surgery,melagatran same day, then ximelagatran 8–24 mg orally b.d. for 7–10 days versus Dalteparin 5000 IU o.d., started evening before surgery for 7–10 days | undergoing hip or knee replacement | double-blind Follow-up duration: 7–10 days |
| ximelagatran versus Enoxaparin | |||
| Platinum (Colwell), 2003 | Ximelagatran 24 mg orally b.d., starting at least 12 h after surgery for 7–12 days versus Enoxaparin 30 mg s.c. b.d.,starting at least 12 h after surgery for 7–12 days | adults undergoing hip replacement | double-blind Follow-up duration: 7–12 days USA, Canada, Israel, Mexico,Argentina, South Africa |
| METHRO III, 2002 | Melagatran 3 mg s.c. 4–12h after surgery, then ximelagatran24 mg orally b.d. for 7–10 days versus Enoxaparin 40 mg s.c. o.d. 12 h before surgery for 7–10 days | hip or knee replacement | double-blind Follow-up duration: 8–11 days Europe, South Africa |
| Phase II (Heit), 2001 | Ximelagatran 8, 12, 18 or 24 mgorally b.d., at least 12 h after surgery for 6–12 days versus Enoxaparin 30 mg s.c. b.d.,starting at least 12 h after surgery for 6–12 days | adults (age>18 years and weight at least 40 kg) undergoing knee replacements | double-blind Follow-up duration: 6–12 days North American |
| EXPRESS, 2003 | Melagatran 2 mg s.c. up to 30 min before surgery, then melagatran 3 mg at least 8 hafter surgery, then ximelagatran 24 mg orally b.d. for 8–11 days versus Enoxaparin 40 mg s.c. o.d.,starting 12 h before surgery for 8–11 days | hip or knee replacement | double-blind Follow-up duration: 8–11 days Europe |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
